Peter Buontempo

519 total citations
16 papers, 366 citations indexed

About

Peter Buontempo is a scholar working on Infectious Diseases, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Peter Buontempo has authored 16 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 7 papers in Molecular Biology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Peter Buontempo's work include Viral Infections and Immunology Research (5 papers), HIV Research and Treatment (4 papers) and Viral gastroenteritis research and epidemiology (4 papers). Peter Buontempo is often cited by papers focused on Viral Infections and Immunology Research (5 papers), HIV Research and Treatment (4 papers) and Viral gastroenteritis research and epidemiology (4 papers). Peter Buontempo collaborates with scholars based in United States, United Kingdom and Australia. Peter Buontempo's co-authors include Juliette O’Connell, Stuart Cox, Viyyoor Girijavallabhan, Edward J. Rozhon, Angela Skelton, John A. Howe, Robert A. Ogert, Robert Ralston, Lei Ba and Julie Strizki and has published in prestigious journals such as Blood, Journal of Virology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Peter Buontempo

15 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Buontempo United States 9 204 159 111 99 96 16 366
Joan C. Enterline United States 10 121 0.6× 100 0.6× 41 0.4× 91 0.9× 129 1.3× 16 333
Hangchun Zhang United States 5 166 0.8× 242 1.5× 95 0.9× 131 1.3× 26 0.3× 7 501
Li‐Ying Liou United States 8 142 0.7× 60 0.4× 199 1.8× 69 0.7× 267 2.8× 8 541
Shringar Rao Netherlands 11 91 0.4× 62 0.4× 116 1.0× 42 0.4× 78 0.8× 20 385
Long-ding Liu China 11 158 0.8× 211 1.3× 21 0.2× 150 1.5× 91 0.9× 34 389
Wangheng Hou China 11 163 0.8× 79 0.5× 19 0.2× 100 1.0× 46 0.5× 26 367
D.C. Pevear United States 7 173 0.8× 200 1.3× 13 0.1× 227 2.3× 37 0.4× 9 429
Anthea L. Hammond United States 8 97 0.5× 35 0.2× 82 0.7× 362 3.7× 62 0.6× 14 473
Naoto Mamiya Japan 9 149 0.7× 20 0.1× 104 0.9× 67 0.7× 42 0.4× 17 387
Gilberto Betancor United Kingdom 11 154 0.8× 17 0.1× 213 1.9× 60 0.6× 95 1.0× 16 316

Countries citing papers authored by Peter Buontempo

Since Specialization
Citations

This map shows the geographic impact of Peter Buontempo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Buontempo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Buontempo more than expected).

Fields of papers citing papers by Peter Buontempo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Buontempo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Buontempo. The network helps show where Peter Buontempo may publish in the future.

Co-authorship network of co-authors of Peter Buontempo

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Buontempo. A scholar is included among the top collaborators of Peter Buontempo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Buontempo. Peter Buontempo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Phares, Timothy W., Vinayaka Kotraiah, Deshapriya S. Karunarathne, et al.. (2020). A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model. Frontiers in Immunology. 11. 1377–1377. 7 indexed citations
2.
Phares, Timothy W., Vinayaka Kotraiah, Chun‐Shiang Chung, et al.. (2020). A Peptide-Based Checkpoint Immunomodulator Alleviates Immune Dysfunction in Murine Polymicrobial Sepsis. Shock. 55(6). 806–815. 15 indexed citations
3.
Nugent, William H., et al.. (2019). Microvascular and systemic responses to novel PEGylated carboxyhaemoglobin-based oxygen carrier in a rat model of vaso-occlusive crisis. Artificial Cells Nanomedicine and Biotechnology. 47(1). 95–103. 5 indexed citations
4.
5.
Krämer, Susanne, Peter Buontempo, Sony Agrawal, & Robert Ralston. (2011). Imaging-Based Assay for Identification and Characterization of Inhibitors of CXCR4-Tropic HIV-1 Envelope-Dependent Cell-Cell Fusion. SLAS DISCOVERY. 16(6). 668–675. 3 indexed citations
6.
Buontempo, Peter, Lisa Wojcik, Robert A. Ogert, et al.. (2009). Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor. Virology. 395(2). 268–279. 4 indexed citations
7.
Ogert, Robert A., Lei Ba, Yan Hou, et al.. (2009). Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc. Journal of Virology. 83(23). 12151–12163. 31 indexed citations
8.
9.
Buontempo, Peter, et al.. (2006). Antiviral Activity of Transiently Expressed IFN-κ Is Cell-Associated. Journal of Interferon & Cytokine Research. 26(1). 40–52. 17 indexed citations
10.
O’Connell, Juliette, Stuart Cox, Peter Buontempo, et al.. (2003). Primary Human Hepatocyte Culture for the Study of HCV. Humana Press eBooks. 19. 495–500. 1 indexed citations
11.
Chase, Robert A., Eric Ferrari, Angela Skelton, et al.. (1997). SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2. Antiviral Research. 35(3). 139–146. 27 indexed citations
12.
Buontempo, Peter, Stuart Cox, Jacquelyn Wright-Minogue, et al.. (1997). SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrobial Agents and Chemotherapy. 41(6). 1220–1225. 45 indexed citations
13.
14.
Cox, Stuart, Peter Buontempo, Jacquelyn Wright-Minogue, et al.. (1996). Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies. Antiviral Research. 32(2). 71–79. 22 indexed citations
15.
Buontempo, Peter, et al.. (1995). Mechanism of action of SCH 47802, an antipicornavirus molecule. Antiviral Research. 26(3). A346–A346. 1 indexed citations
16.
Rozhon, Edward J., Stuart Cox, Peter Buontempo, et al.. (1993). SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Research. 21(1). 15–35. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan C. Enterline Breakdown of academic impact, for papers by Hangchun Zhang Breakdown of academic impact, for papers by Li‐Ying Liou Breakdown of academic impact, for papers by Shringar Rao Breakdown of academic impact, for papers by Long-ding Liu Breakdown of academic impact, for papers by Wangheng Hou Breakdown of academic impact, for papers by D.C. Pevear Breakdown of academic impact, for papers by Anthea L. Hammond Breakdown of academic impact, for papers by Naoto Mamiya Breakdown of academic impact, for papers by Gilberto Betancor
Rankless by CCL
2026